EMEA Transarterial Radioembolization Market: Focus on Microsphere Type, Indication, Region, and Competitive Landscape - Analysis and Forecast, 2026-2036

This report can be delivered within 1 working day.

Introduction to the EMEA Transarterial Radioembolization Market

The EMEA transarterial radioembolization (TARE) market, valued at $61.0 million in 2024 and $64.7 million in 2025, is projected to reach $146.9 million by 2036, registering a compound annual growth rate (CAGR) of 7.81% during 2026-2036.

The EMEA transarterial radioembolization (TARE) market is expanding as multidisciplinary liver cancer teams increasingly use selective, minimally invasive treatment for suitable patients with primary and metastatic hepatic tumors. TARE, also called selective internal radiation therapy (SIRT), involves image-guided administration of radioactive microspheres through the hepatic arterial circulation to deliver localized beta radiation to liver tumors. This report measures the commercial market for therapeutic Yttrium-90 (Y-90) resin and Y-90 glass microspheres, rather than the entire cost of performing radioembolization procedures. Relevant indications include hepatocellular carcinoma (HCC), colorectal cancer liver metastases (CRLM), intrahepatic cholangiocarcinoma (ICC), neuroendocrine tumor (NET) liver metastases, and other liver metastases. Adoption is driven by growing demand for liver-directed options in unresectable or liver-dominant disease, specialist interventional oncology capabilities, and greater use of patient-specific treatment planning. Clinical selection remains critical because hepatic reserve, tumor distribution, vascular anatomy, prior therapy, and treatment intent determine appropriateness.

Advances in TARE practice are changing how clinicians plan and deliver radioembolization. Quantitative SPECT/CT, Y-90 PET/CT, improved angiographic mapping, selective microcatheter techniques, and personalized absorbed-dose assessment are supporting more precise treatment. Radiation segmentectomy and superselective administration are extending the clinical discussion beyond conventional lobar treatment into selected early-stage or anatomically challenging HCC. Commercial competition remains concentrated around Sirtex Medical's SIR-Spheres resin microspheres and Boston Scientific's TheraSphere glass microspheres. Clinical-stage platforms, including imageable and alternative-carrier microspheres, are assessed as potential future competitors but are not added to current quantitative revenues without qualifying commercial sales. Market expansion is nevertheless constrained by the cost and complexity of mapping and dosimetry, radiation-safety requirements, specialist staffing, variable reimbursement, and competition from TACE, surgery, thermal ablation, SBRT, and systemic therapies. Broader clinical evidence, improved access, and carefully selected combinations with systemic treatment present longer-term opportunities.

Market Introduction

The EMEA TARE market has evolved as radioembolization becomes an increasingly established liver-directed option within specialized oncology pathways. Suppliers are refining Y-90 microsphere delivery, treatment planning, clinical evidence, and dosimetry practices to improve precision and reproducibility. Resin and glass microspheres differ in particle composition, activity per microsphere, embolic characteristics, and treatment protocols. Use extends from conventional lobar radioembolization to segmental, selective, and superselective approaches, including radiation segmentectomy for appropriately selected HCC. The procedure requires coordinated assessment by interventional radiologists, nuclear medicine specialists, dosimetrists, hepatologists, and oncologists, with the overall goal of tumor radiation dose management while preserving healthy liver.

Important innovations include patient-specific dosimetry, pre-treatment 99mTc-MAA mapping, quantitative post-treatment imaging, radiation segmentectomy, and improved delivery systems. These developments support individualized tumor targeting and a more defined role for TARE in bridging, downstaging, disease control, and selected ablative-intent settings. Europe remains the main commercial market, reflecting experienced treatment centers and comparatively mature reimbursement pathways, whereas adoption in the Middle East and Africa is more uneven. Growth is expected as interventional oncology infrastructure improves, particularly in selected Middle Eastern markets. Clinical-stage alternatives and combination-therapy research could further influence the market, but regulatory clearance and commercial adoption remain necessary before emerging platforms contribute to the measured market.

Industrial Impact

The EMEA transarterial radioembolization market is influenced by the growing role of image-guided interventional oncology in managing liver-dominant malignancies. Sirtex Medical and Boston Scientific Corporation are the principal established commercial suppliers through SIR-Spheres Y-90 resin and TheraSphere Y-90 glass microspheres, respectively. Both platforms enable selective hepatic-arterial radiation delivery, but differ in particle properties, activity per microsphere, and treatment-planning considerations. Their clinical evidence, product supply networks, and treatment-planning improvements are central to adoption. Emerging companies such as ABK Biomedical, Chengdu New Radiomedicine Technology Co., Ltd., and Cerenome are developing differentiated platforms. The broader industrial impact extends to interventional radiology, nuclear medicine, medical physics, hepatology, and oncology services. Adoption is facilitated where experienced centers can conduct angiographic mapping, lung-shunt assessment, patient-specific dosimetry, radiation-safety procedures, and outcome monitoring. Growing interest in precise treatment delivery and specialist training increases the importance of reimbursement, product availability, physician confidence, and demonstrated clinical benefit in HCC and selected metastatic liver cancers.

Market Segmentation:

Segmentation 1: By Microsphere Type

• Yttrium-90 Resin Microspheres
• Yttrium-90 Glass Microspheres

Yttrium-90 Glass Microspheres Segment to Emerge as the Leading Segment During the Forecast Period in EMEA Transarterial Radioembolization Market (by Microsphere Type)

On the basis of microsphere type, the Y-90 glass microspheres segment is expected to hold the largest share in the EMEA transarterial radioembolization market. The Yttrium-90 (Y-90) glass microspheres segment is expected to lead the EMEA transarterial radioembolization (TARE) market during the forecast period, surpassing Y-90 resin microspheres, which held a marginally higher market value in 2025. This anticipated growth is primarily driven by the established clinical adoption of glass microspheres in high-dose selective treatments, particularly radiation segmentectomy for hepatocellular carcinoma (HCC). The higher radioactivity per microsphere enables targeted radiation delivery with fewer microspheres and a lower embolic load, supporting precise and selective treatment approaches.

Segmentation 2: By Indication

• Hepatocellular Carcinoma
• Colorectal Cancer Liver Metastases
• Intrahepatic Cholangiocarcinoma
• Neuroendocrine Tumor Liver Metastases
• Other Liver Metastases

Hepatocellular Carcinoma to Lead the EMEA Transarterial Radioembolization Market (by Indication)

On the basis of indication, the hepatocellular carcinoma segment is expected to hold the largest share in the EMEA transarterial radioembolization market. This dominance is primarily driven by the established clinical use of TARE as a liver-directed treatment option for selected patients with unresectable HCC. Its adoption across specific treatment settings, including radiation segmentectomy and intermediate-stage disease management, continues to support segment growth. Additionally, the substantial disease burden of HCC, increasing integration of minimally invasive liver-directed therapies into multidisciplinary treatment pathways, and advancements in patient selection and personalized dosimetry are expected to strengthen market demand.

Segmentation 3: By Region

• Europe
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Rest-of-Europe
• Middle East and Africa
  • U.A.E.
  • K.S.A.
  • South Africa
  • Rest-of-Middle East and Africa

Europe Region to Lead the EMEA Transarterial Radioembolization Market (by Region)

On the basis of region, Europe is expected to hold the largest share in the EMEA transarterial radioembolization market. Europe's leadership is supported by its established interventional imaging and nuclear medicine infrastructure, experienced multidisciplinary treatment centers, and more developed reimbursement and referral pathways.

Recent Developments in the EMEA Transarterial Radioembolization Market

• In June 2026, Chengdu New Radiomedicine Technology reported Phase I clinical-study findings for its investigational Y-90 carbon microspheres (NRT6003 Injection) at the ASCO Annual Meeting, advancing its clinical-stage radioembolization program.
• In April 2026, ABK Biomedical partnered with COR Development to establish a commercial-scale GMP manufacturing facility for Eye90 microspheres. The initiative supports future manufacturing readiness; the platform remains under development.
• In September 2025, Sirtex Medical received expanded CE Mark approval for SIR-Spheres Y-90 resin microspheres, expanding eligibility to patients with both primary and secondary liver metastases and broadening access to TARE across Europe and other CE-marked territories.

Demand - Drivers, Challenges, and Opportunities

Market Drivers

Growing Adoption of Personalized Dosimetry: The increasing adoption of personalized dosimetry is expected to drive growth in the EMEA transarterial radioembolization (TARE) market, as healthcare providers increasingly focus on improving treatment precision and clinical outcomes. Unlike conventional dosing approaches, personalized dosimetry enables treatment planning based on patient-specific factors, including tumor size, disease distribution, and liver function, allowing more targeted radiation delivery while minimizing exposure to healthy liver tissue. Advancements in imaging technologies, treatment planning software, and dose optimization techniques are further supporting the integration of personalized dosimetry into routine clinical practice. Additionally, growing clinical evidence supporting improved treatment responses and the increasing preference for individualized liver-directed therapies are expected to encourage wider adoption of TARE across specialized oncology centers in EMEA during the forecast period.

Market Challenges

Competition from Established Treatment Modalities: The availability and widespread clinical adoption of established treatment modalities are expected to restrain the growth of the EMEA transarterial radioembolization (TARE) market. Treatment options such as transarterial chemoembolization (TACE), thermal ablation, surgical resection, and systemic therapies are well integrated into existing liver cancer management pathways, supported by extensive clinical experience and established treatment guidelines. TACE remains a commonly utilized locoregional therapy for intermediate-stage hepatocellular carcinoma (HCC), while thermal ablation and surgical resection are frequently preferred for patients with small, localized, or resectable tumors. Additionally, advancements in immunotherapy and targeted systemic treatments are expanding therapeutic options for patients with advanced liver cancer, further influencing the selection of liver-directed therapies. Factors such as physician familiarity, treatment availability, institutional expertise, and established reimbursement pathways continue to influence treatment decisions across EMEA. Consequently, the strong presence of alternative treatment modalities may limit the broader adoption of TARE, particularly in healthcare settings where conventional treatment approaches are already well established.

Market Opportunities

Expansion into Earlier-Stage and Curative-Intent Treatment: The expanding application of transarterial radioembolization (TARE) in earlier-stage liver cancer and curative-intent treatment settings presents a significant growth opportunity for the EMEA TARE market. Traditionally utilized for patients with unresectable liver tumors, TARE is increasingly being explored as a treatment option for selected patients with early-stage hepatocellular carcinoma (HCC), particularly those who are unsuitable for surgical resection or thermal ablation. Advancements in catheter-based delivery techniques, imaging technologies, and personalized dosimetry are enabling more precise administration of high radiation doses to targeted liver segments while limiting exposure to surrounding healthy tissue. The growing clinical interest in radiation segmentectomy, which aims to achieve durable local tumor control through selective radiation delivery, is further supporting this shift toward curative-intent applications. Additionally, the use of TARE for tumor downstaging and as a bridge to liver transplantation or surgical resection is expected to expand its potential patient population. Increasing clinical evidence, continued technological advancements, and greater integration into multidisciplinary liver cancer treatment pathways are anticipated to create new opportunities for TARE adoption across specialized oncology centers in EMEA during the forecast period.

How can this report add value to an organization?

Product/Innovation Strategy: The EMEA transarterial radioembolization (TARE) market has been segmented based on key categories, including microsphere type and indication. By analyzing the market share, growth potential, and adoption trends across these segments, the report provides insights into emerging opportunities for product innovation, treatment expansion, and market penetration. It also supports companies in aligning their product portfolios and development strategies with evolving clinical requirements, increasing adoption of personalized dosimetry, and growing demand for targeted liver-directed therapies across EMEA.

Growth/Marketing Strategy: Strategic partnerships, collaborations, product innovations, regulatory approvals, and geographic expansion are expected to play a significant role in the growth of the EMEA transarterial radioembolization (TARE) market. Collaborations between microsphere manufacturers, healthcare institutions, interventional radiologists, and research organizations are supporting clinical adoption, treatment optimization, and expansion into new indications. This report supports organizations in identifying market entry opportunities, evaluating country-level growth potential, and developing commercialization strategies aligned with evolving clinical practices and reimbursement frameworks across EMEA.

Competitive Strategy: The EMEA transarterial radioembolization (TARE) market is characterized by the presence of established microsphere manufacturers, including Boston Scientific Corporation and Sirtex Medical, alongside emerging companies developing next-generation radioembolization technologies. Market participants are focusing on product differentiation through microsphere composition, radiation delivery characteristics, personalized dosimetry capabilities, and clinical evidence supporting treatment efficacy across liver cancer indications. Increasing emphasis on technological advancements, clinical research, physician training, and strategic collaborations is shaping the competitive landscape. This report enables organizations to assess competitor positioning, compare product portfolios, identify market gaps, and evaluate opportunities for strategic partnerships, geographic expansion, and product development within the EMEA TARE market.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

• Years from 2024 to 2036 have been considered for the market size estimation; 2025 has been considered as the base year, and 2026 to 2036 as the forecast period.
• The scope of the report is based on comprehensive inputs from industry experts and key stakeholders across the EMEA transarterial radioembolization (TARE) market, including interventional radiologists, nuclear medicine specialists, oncologists, hospitals, specialized liver cancer treatment centers, and industry participants involved in radioembolization procedures.
• The market contribution of transarterial radioembolization is anticipated to witness continued growth in the future, with projections based on historical analysis of available products.
• Revenues from companies have been sourced from their annual reports for FY2024 and FY2025. For private companies, revenue estimates are derived from primary research inputs, funding history, market collaborations, and operational performance.
• The market has been mapped based on commercially available Y-90 glass and resin microsphere products used in TARE procedures across EMEA. Key companies with established commercial offerings and emerging participants developing radioembolization technologies have been identified and profiled in this report.

Primary Research

The primary sources involve industry experts and key stakeholders across the EMEA transarterial radioembolization (TARE) market, including microsphere manufacturers, medical device companies, interventional radiologists, nuclear medicine specialists, oncologists, and healthcare institutions. Stakeholders from hospitals, specialized liver cancer treatment centers, and interventional oncology departments have been consulted to validate treatment adoption trends, procedure volumes, clinical applications, and market dynamics. Respondents, including CEOs, vice presidents, product and marketing directors, commercial strategy leaders, and clinical specialists, have been interviewed to obtain and validate qualitative and quantitative insights for this research study.

The key data points taken from the primary sources include:

• validation and triangulation of all the numbers and graphs
• validation of report segmentations and key qualitative findings
• understanding the competitive landscape and business model
• current and proposed production values of a product by market players
• validation of the numbers of different segments of the market in focus
• percentage split of individual markets for regional analysis

Secondary Research

Open Sources

• Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
• Annual reports, SEC filings, and investors' presentations of the leading market players
• Company websites and a detailed study of their product portfolio
• Gold standard magazines, journals, white papers, press releases, and news articles
• Paid databases

The key data points taken from the secondary sources include:

• segmentations and percentage shares
• data for market value
• key industry trends of the top players in the market
• qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
• quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from an analysis of company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

• Sirtex Medical
• Boston Scientific
• ABK Biomedical
• Chengdu New Radiomedicine Technology Co., Ltd.
• Cerenome